Obesity (Silver Spring, Md.)最新文献

{"title":"Weight loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk.","authors":"Léa Karam, Julien Paccou","doi":"10.1002/oby.24341","DOIUrl":"10.1002/oby.24341","url":null,"abstract":"","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variations in weight loss and glycemic outcomes after sleeve gastrectomy by race and ethnicity.","authors":"Sally M Vanegas, Silvia Curado, Boyan Zhou, Nicholas Illenberger, Ericka N Merriwether, Evelyn Armijos, Ann Marie Schmidt, Christine Ren-Fielding, Manish Parikh, Brian Elbel, José O Alemán, Melanie Jay","doi":"10.1002/oby.24320","DOIUrl":"https://doi.org/10.1002/oby.24320","url":null,"abstract":"<p><strong>Objective: </strong>This study examined racial and ethnic differences in percent total weight loss (%TWL) and glycemic improvement following sleeve gastrectomy (SG) and explored the role of socioeconomic and psychosocial factors in postsurgical outcomes.</p><p><strong>Methods: </strong>This longitudinal study included patients who underwent SG between 2017 and 2020, with follow-up visits over 24 months.</p><p><strong>Results: </strong>Non-Hispanic Black (NHB) participants had lower %TWL at 3, 12, and 24 months compared with Hispanic (H) and non-Hispanic White (NHW) participants. Fat mass index was initially lower in NHB, with smaller reductions over time and significant group differences persisting at 24 months. NHB participants had higher baseline fat-free mass index values; by 24 months, fat-free mass index values were lower in H participants. Hemoglobin A1c decreased across all groups but remained consistently higher in NHB and H compared with NHW at 24 months. NHB participants reported higher perceived discrimination, sleep disturbance, and perceived stress than H and NHW participants at all time points. Employment status predicted %TWL at 12 months. There was a significant interaction between race and ethnicity and employment status observed at 12 and 24 months, suggesting that employment-related disparities could impact surgical outcomes.</p><p><strong>Conclusions: </strong>NHB participants experienced less favorable outcomes following SG, emphasizing the need for tailored interventions addressing socioeconomic and psychosocial disparities.</p>","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of obesity-associated plasma markers on adipose stem cell function and epigenetic regulation.","authors":"Andressa França Sousa Bispo, Jussara de Jesus Simao, Miguel Ambrizzi Moraes, Ana Beatriz Marques Abel, Victor Tadeu Gonçalves Plata, Monica Marques Telles, André Valente Santana, Paula Volpe, Lucia Maria Armelin-Correa, Maria Isabel Cardoso Alonso-Vale","doi":"10.1002/oby.24321","DOIUrl":"https://doi.org/10.1002/oby.24321","url":null,"abstract":"<p><strong>Objective: </strong>This study investigates the correlations between obesity-related plasma markers and epigenetic/inflammatory changes in white adipose tissue (WAT), focusing on adipose-derived stem cells (ASCs). We hypothesize that obesity modulates histone H3K27 marks, modified by demethylases (lysine-specific demethylase 6A and 6B [KDM6A/KDM6B]) and acetylases (CREB-binding protein [CREBBP]/histone acetyltransferase EP300), affecting ASC function.</p><p><strong>Methods: </strong>Serum and visceral WAT (omental region) was collected from male patients (n = 16, 30-50 years old) undergoing elective gastric or bariatric surgery. BMI and obesity markers were correlated with changes in ASCs (transcript expression, proliferation, and secretion) using reverse transcriptase-polymerase chain reaction.</p><p><strong>Results: </strong>ASCs from individuals with higher BMI exhibited slower proliferation, increased inflammatory profile, and reduced adipogenic potential, with lower expression of key adipogenic genes. H3K27 acetylase transcripts were also negatively correlated with adipogenesis regulators. Moreover, C-C motif chemokine 2 (CCL2) and KDM6A expression was higher in the group with obesity, as were CREBBP and EP300. Finally, leptin levels positively correlated with serum, WAT, and ASC CCL2 expression. In vitro, leptin exposure enhanced CCL2 expression/secretion and increased KDM6A/KDM6B and EP300 transcription.</p><p><strong>Conclusions: </strong>In vitro leptin exposure enhanced CCL2 expression/secretion and increased KDM6A/KDM6B and EP300 transcription, highlighting how obesity-driven epigenetic mechanisms, including leptin-mediated pathways, disrupt ASC plasticity and perpetuate adipose tissue dysfunction, offering novel therapeutic targets for metabolic disease intervention.</p>","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status.","authors":"Hamlet Gasoyan, W Scott Butsch, Rebecca Schulte, Nicholas J Casacchia, Phuc Le, Christopher B Boyer, Marcio L Griebeler, Bartolome Burguera, Michael B Rothberg","doi":"10.1002/oby.24331","DOIUrl":"https://doi.org/10.1002/oby.24331","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to characterize changes in body weight and glycated hemoglobin (in those with prediabetes at baseline) through 12 months by obesity pharmacotherapy discontinuation status.</p><p><strong>Methods: </strong>This retrospective cohort study used electronic health record data from a large health system in Ohio and Florida to identify adults with overweight or obesity without type 2 diabetes who initiated injectable semaglutide or tirzepatide between 2021 and 2023. Treatment discontinuation was defined by a >90-day gap between exhaustion of previous supply and next dispense or end of study follow-up (December 2024) and was classified into early discontinuation (i.e., within 3 months of index date) and late discontinuation (i.e., within 3-12 months).</p><p><strong>Results: </strong>We identified 7881 patients; 6109 received semaglutide, and 1772 received tirzepatide. A total of 80.8% had low maintenance dosages. Mean (SD) percentage weight reduction at 1 year was 8.7% (9.6%); and it was 3.6% (8.1%) with early discontinuation, 6.8% (9.1%) with late discontinuation, and 11.9% (9.2%) with non-discontinuation (p < 0.001). The mean (SD) absolute reduction in percent glycated hemoglobin at 1 year was 0.1 (0.4) with early discontinuation, 0.2 (0.4) with late discontinuation, and 0.4 (0.4) with non-discontinuation (p < 0.001).</p><p><strong>Conclusions: </strong>The average weight reduction in this cohort was lower than that observed in the main phase 3 trials, likely because of higher rates of discontinuation and lower maintenance dosages.</p>","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.","authors":"Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M Apovian, Shagun Bindlish, Jonathan Bonnet, W Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M Kane, Jasdeep Saluja, Deepa Sannidhi, Fatima Cody Stanford, Emily A Callahan","doi":"10.1002/oby.24336","DOIUrl":"https://doi.org/10.1002/oby.24336","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Glucagon-like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP-1s) are shifting the treatment landscape for obesity. However, real-world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP-1 efficacy, equitable results, and cost-effectiveness.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;We aimed to identify pragmatic priorities for nutrition and other lifestyle interventions relevant to GLP-1 treatment of obesity for the practicing clinician.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;An expert group comprising multiple clinical and research disciplines appraised the scientific literature, informed by expert knowledge and clinical experience, to identify and summarize relevant topics, priorities, and emerging directions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;GLP-1s reduce body weight by 5% to 18% in trials, with modestly lower effects in real-world analyses, and multiple demonstrated clinical benefits. Challenges include side effects, especially gastrointestinal; nutritional deficiencies due to calorie reduction; muscle and bone loss; low long-term adherence with subsequent weight regain; and high costs with resulting low cost-effectiveness. Numerous practice guidelines recommend multicomponent, evidence-based nutritional and behavioral therapy for adults with obesity, but use of such therapies with GLP-1s is not widespread. Priorities to address this include: (a) patient-centered initiation of GLP-1s, including goals for weight reduction and health; (b) baseline screening, including usual dietary habits, emotional triggers, disordered eating, and relevant medical conditions; (c) comprehensive exam including muscle strength, function, and body composition assessment; (d) social determinants of health screening; (e) and lifestyle assessment including aerobic activity, strength training, sleep, mental stress, substance use, and social connections. During GLP-1 use, nutritional and medical management of gastrointestinal side effects is critical, as is navigating altered dietary preferences and intakes, preventing nutrient deficiencies, preserving muscle and bone mass through resistance training and appropriate diet, and complementary lifestyle interventions. Supportive strategies include group-based visits, registered dietitian nutritionist counseling, telehealth and digital platforms, and Food is Medicine interventions. Drug access, food and nutrition insecurity, and nutrition and culinary knowledge influence equitable obesity management with GLP-1s. Emerging areas for more study include dietary modulation of endogenous GLP-1, strategies to improve compliance, nutritional priorities for weight maintenance post-cessation, combination or staged intensive lifestyle management, and diagnostic criteria for clinical obesity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Evidence-based nutritional and lifestyle strategies play a pivotal role to address","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic and environmental contributions to the associations between midlife personality and late-life metabolic health.","authors":"Colin D Freilich, Jacob J Kunkel, Keely A Dugan, Elise J Vomacka, Adolfo G Cuevas, Kristian Markon, Matt McGue, Glenn I Roisman, Robert F Krueger","doi":"10.1002/oby.24268","DOIUrl":"10.1002/oby.24268","url":null,"abstract":"<p><strong>Objective: </strong>Personality traits such as conscientiousness and emotional stability are consistently linked with better metabolic health, but there is limited evidence on the etiology of these associations and their robustness across the life-span.</p><p><strong>Methods: </strong>Therefore, we estimated phenotypic, genetic, and unique environmental associations of traits indexed by the Multidimensional Personality Questionnaire in early-to-middle adulthood (mean age = 38.3 years) with BMI, waist circumference, high-density lipoprotein cholesterol, C-reactive protein, triglycerides, and glycated hemoglobin in older adulthood (mean age = 70.4 years) using the Minnesota Twin Registry sample (n = 950).</p><p><strong>Results: </strong>Traits that indexed emotional instability in midlife, such as alienation and stress reactivity, were significant predictors of several metabolic outcomes late in life (bivariate |r| ≤ 0.22), whereas negative associations with traits related to conscientiousness (e.g., control, constraint, achievement) tended to be more modest. For most traits that were phenotypically associated, we observed significant genetic correlations. Additionally, alienation and stress reactivity had weak-to-moderate unique environmental correlations with BMI, waist circumference, and C-reactive protein (r_e = 0.10-0.29).</p><p><strong>Conclusions: </strong>These results are consistent with an etiology of declining metabolic health into old age involving the propensity toward negative affective experiences decades prior, further validating the health relevance of individual differences in personality.</p>","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of lifestyle-based weight loss in older adults with obesity on muscle and bone health: a balancing act.","authors":"Tiffany M Cortes, Kacey Chae, Colleen M Foy, Denise K Houston, Kristen M Beavers","doi":"10.1002/oby.24229","DOIUrl":"10.1002/oby.24229","url":null,"abstract":"<p><p>Despite adverse metabolic and functional consequences of obesity (BMI ≥30 kg/m²), clinical recommendations for weight loss (WL) in older adults (65+ years) with obesity remain controversial. Reluctance stems partly from epidemiologic data demonstrating musculoskeletal tissue loss with WL and increased risk of disability and osteoporotic fracture. Randomized controlled trials in older adults complement and extend knowledge in this area showing: (1) lifestyle-based WL interventions often yield clinically meaningful (~8%-10%) WL in older adults; (2) lean mass loss is significant, although fat mass loss is preferential and physical performance is often improved, particularly when combined with aerobic and resistance training (RT); (3) bone loss is also significant, with some evidence that RT can attenuate WL-associated bone loss; and (4) fat mass regain after intervention cessation is common, yet physical performance gains appear to be maintained. Best practices for treating older adults with obesity include comprehensive assessment of baseline musculoskeletal health; patient-centered goal setting; moderate (i.e., -500 kcal/day) caloric restriction ensuring protein (1-1.2 g/kg/day), calcium (1000-1200 mg/day), and vitamin D (800-1000 IU/day) needs are met; incorporation of RT (≥2 days/week) and moderate-intensity weight-bearing aerobic training (≥150 min/week); and delivery of care by a multidisciplinary team.</p>","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BMI-for-age percentile curves for older adults.","authors":"Hailey R Banack, Christopher D Kim, Claire E Cook, Alexandra Wasser, Jay S Kaufman, Steven D Stovitz","doi":"10.1002/oby.24189","DOIUrl":"10.1002/oby.24189","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this manuscript is to present BMI-for-age percentile curves for men and women aged 45 to 90 years.</p><p><strong>Methods: </strong>Weighted empirical percentile estimates were calculated using data from the Canadian Longitudinal Study on Aging (CLSA) comprehensive cohort (2011-2018) according to age and sex. Statistical smoothing procedures were used to generate smoothed curves for the percentile values. Overweight and obesity were defined as BMI greater than the 85th and 95th percentile for age and sex, respectively.</p><p><strong>Results: </strong>In order to create BMI-for-age percentile curves, n = 56,705 observations were used (n = 29,961 individuals at baseline and n = 26,744 individuals at the first follow-up visit). In men, absolute values for BMI percentiles are lower than those in women, and the decline in BMI begins earlier (i.e., at a younger age). In women, the 95th percentile threshold for BMI is highest between ages 59 and 67 years (i.e., 41 kg/m²), and in men, the 95th percentile threshold for BMI is highest between ages 51 and 62 years (i.e., 39 kg/m²).</p><p><strong>Conclusions: </strong>BMI-for-age percentile curves demonstrate how an individual's BMI value compares with values from a reference population comprising individuals of the same age and sex. This approach has widespread utility to determine eligibility for interventions and as a tool to incorporate into clinical models of care for obesity management in an aging population.</p>","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Musculoskeletal characteristics in older adults with overweight or obesity: INVEST in Bone Health trial baseline analysis.","authors":"S Delanie Lynch, Marjorie Howard, Daniel P Beavers, Leon Lenchik, Ryan Barnard, Joshua R Stapleton, Erica Lawrence, Peggy M Cawthon, Fang-Chi Hsu, Kristen M Beavers, Ashley A Weaver","doi":"10.1002/oby.24243","DOIUrl":"10.1002/oby.24243","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to examine associations of computed tomography (CT)-derived musculoskeletal measures with demographics and traditional musculoskeletal characteristics.</p><p><strong>Methods: </strong>The Incorporating Nutrition, Vests, Education, and Strength Training (INVEST) in Bone Health trial (NCT04076618) acquired a battery of musculoskeletal measures in 150 older-aged adults living with overweight or obesity. At baseline, CT (i.e., volumetric bone mineral density, cortical thickness, muscle radiomics, and muscle/intermuscular adipose tissue [IMAT] area and density), dual-energy x-ray absorptiometry (DXA; i.e., areal bone mineral density, total body fat mass, appendicular lean mass, and lean body mass), and strength assessments (i.e., grip and knee extensor strength) were collected, along with demographic and clinical characteristics. Analyses employed linear regression and mixed-effects models along with factor analysis for dimensionality reduction of the radiomics data.</p><p><strong>Results: </strong>Participants were older-aged (mean [SD] age: 66 [5] years), mostly female (75%), and were living with overweight or obesity (mean [SD] BMI: 33.6 [3.3] kg/m²). Age was not significantly associated with most CT-derived bone, IMAT, or muscle measures. BMI was significantly associated with DXA and CT-derived muscle and IMAT measures, which were higher in male than female individuals (all p < 0.01). For the midthigh, muscle size was significantly related to grip and knee extensor strength (both p < 0.01).</p><p><strong>Conclusions: </strong>Machine learning-derived CT metrics correlated strongly with DXA and muscle strength, with higher BMI linked to greater IMAT and poorer muscle quality.</p>","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of antiobesity medications for weight reduction in older adults: a systematic review.","authors":"Alissa S Chen, Alexandra M Hajduk, Alyssa A Grimshaw, Terri R Fried, Ania M Jastreboff, Kasia J Lipska","doi":"10.1002/oby.24160","DOIUrl":"10.1002/oby.24160","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to examine weight reduction and adverse events associated with use of antiobesity medications (AOMs) in older adults ages ≥65 years.</p><p><strong>Methods: </strong>Seven databases were searched for studies evaluating weight reduction of Food and Drug Administration (FDA)-approved AOMs. Studies had to include adults ages ≥65 years with obesity (BMI ≥ 30 kg/m² or ≥27 kg/m² with one weight-related condition), with independent analysis of weight reduction for adults ages ≥65 years. Two coauthors extracted and evaluated studies for risk of bias using standardized forms.</p><p><strong>Results: </strong>Six experimental studies (five secondary analyses of randomized clinical trial data and one single-arm trial) and two observational studies met inclusion criteria. Seven medications were studied. Sample size of older adults ranged from 13 to 6728. Experimental studies predominantly included patients with concurrent prediabetes or cardiovascular disease. All studies found statistically significant weight reduction between intervention and placebo groups or compared with baseline weight. Few studies reported on adverse events.</p><p><strong>Conclusions: </strong>Limited evidence suggests weight reduction of AOMs in older adults, with the best current evidence for the use of semaglutide in older adults with obesity and cardiovascular disease. Larger, more inclusive studies of older adults are needed to guide clinical care and determine the tolerability of AOMs for older adults.</p>","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}